Tissue Therapies Limited  

(Public, ASX:TIS)   Watch this stock  
Find more results for TIS
+0.0050 (11.11%)
Oct 9 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.05 - 0.05
52 week 0.03 - 0.37
Open 0.05
Vol / Avg. 10,000.00/106,481.00
Mkt cap 15.14M
P/E     -
Div/yield     -
EPS -0.04
Shares 302.88M
Beta     -
Inst. own     -
Nov 25, 2015
Tissue Therapies Ltd Annual Shareholders Meeting - 1:30PM GMT+11 - Add to calendar
Oct 7, 2015
Tissue Therapies Ltd Annual Shareholders Meeting (Estimated)

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -1385.21% -2132.07%
Operating margin -1327.35% -2113.22%
EBITD margin - -2097.89%
Return on average assets -86.73% -65.92%
Return on average equity -97.62% -74.33%
CDP Score - -


L 19 179 Turbot St
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Tissue Therapies Limited is an Australia-based biomedical technology company which develops and manufactures proteins for healing wounds. The Company provides effective treatments for acute and chronic wound, including chronic skin ulcers and burns. The company also provides treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. VitroGro ECM, a product of Tissue Therapies, is a solution of synthetic protein that promotes healing and reduces pain in chronic wounds. The product is applied to the surface of a prepared wound and the liquid formulation allows the product to cover the irregular shape of the wound. Tissue Therapies Europe Limited a wholly owned subsidiary which is set up to provide administration support to Tissue Therapies Limited.

Officers and directors

Nigel Johnson Acting Chief Executive Officer
Zee Upton Chief Scientific Officer
Saskia Jo Company Secretary
Melvyn John Bridges Non-Executive Director
Age: 65
Cherrell Hirst Non-Executive Director
Timothy Richard Hughes Non-Executive Director